"The SEC observed that in view of the safety and immunogenicity data already generated by Dr Reddy’s in India on the first dose component of Sputnik V (in other words, Sputnik Light), there was no need for a separate Phase III trial of Sputnik Light in India," the company said.Dr Reddy#39;s says expert panel sought Phase-3 data of Sputnik V in Russia to consider Sputnik Light
"The SEC observed that in view of the safety and immunogenicity data already generated by Dr Reddy’s in India on the first dose component of Sputnik V (in other words, Sputnik Light), there was no need for a separate Phase III trial of Sputnik Light in India," the company said.
Subscribe to:
Post Comments (Atom)
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
"The (latest) investment will be used to grow the mobile esports format and establish presence in select overseas markets through its ...
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment